Get the Stockscreener App
0.178
5.02%
-0.0074
After Hours:
.18
0.002
+1.12%
Aptose Biosciences Inc stock is traded at $0.178, with a volume of 317.98K.
It is down -5.02% in the last 24 hours and down -22.49% over the past month.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
See More
Previous Close:
$0.1854
Open:
$0.181
24h Volume:
317.98K
Relative Volume:
0.05
Market Cap:
$10.68M
Revenue:
-
Net Income/Loss:
$-35.80M
P/E Ratio:
-0.0599
EPS:
-2.97
Net Cash Flow:
$-37.18M
1W Performance:
+0.06%
1M Performance:
-22.49%
6M Performance:
-64.71%
1Y Performance:
-91.57%
1-Day Range:
$0.1748
$0.1843
1-Week Range:
$0.1722
$0.1944
52-Week Range:
$0.13
$2.1568
Aptose Biosciences Inc Stock (APTO) Company Profile
Name
Aptose Biosciences Inc
Sector
Industry
Phone
310-849-8060
Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Compare APTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.178 | 10.68M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Feb-20-20 | Initiated | Maxim Group | Buy |
| Feb-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | Piper Sandler | Overweight |
| Mar-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Nov-16-18 | Initiated | B. Riley FBR | Buy |
| Dec-13-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-07-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-08-17 | Initiated | Rodman & Renshaw | Neutral |
View All
Aptose Biosciences Inc Stock (APTO) Latest News
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
Aptose Biosciences shareholders approve reverse stock split By Investing.com - Investing.com Canada
Aptose Biosciences Inc. (NASDAQ:APTO) Sees Large Increase in Short Interest - Defense World
Zura Bio (NASDAQ:ZURA) vs. Aptose Biosciences (NASDAQ:APTO) Critical Contrast - Defense World
Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-JAN-2025. - Marketscreener.com
Aptose Biosciences faces Nasdaq delisting over share price - MSN
Aptose Biosciences faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Aptose Biosciences Inc. Files 8-K Report - Defense World
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com - Defense World
Aptose Biosciences Inc. Issues Regulation FD Disclosure in Recent Press Release - Defense World
Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright - Defense World
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial - The Manila Times
Aptose Biosciences Initiates TUSCANY Trial for Frontline AML Therapy - TipRanks
Aptose Launches TUSCANY Trial: Groundbreaking Triple Therapy for Untreated AML Patients - StockTitan
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose Biosciences (NASDAQ: APTO) Announces Regulation FD DisclosureOn December 19, 2024, Aptose Biosciences Inc. issued a press release, providing detailed information on recent developments. The press release specified various financial results - Defense World
Aptose Announces Positive Decision by Nasdaq Hearings Panel - The Manila Times
Aptose gets Nasdaq extension to regain compliance - MSN
Aptose Biosciences Secures Critical Nasdaq Extension, Unveils $8M Offering and Cancer Drug Progress - StockTitan
Metrics That Matter About Aptose Biosciences Inc (NASDAQ: APTO) - Stocks Register
SEC Form PRE 14A filed by Aptose Biosciences Inc. - Quantisnow
Tuspetinib shows promise in AML treatment, study finds By Investing.com - Investing.com UK
Aptose Announces Publication of Preclinical Data in AACR - GlobeNewswire
Aptose's Tuspetinib Shows Breakthrough Potential in Leukemia Treatment, Clinical Data Reveals Powerful Anti-Cancer Effects - StockTitan
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax - Yahoo Finance
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks On TSX (APS) - Barchart
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - The Manila Times
Aptose Clinical Data Featured in Poster Presentation at the - GlobeNewswire
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences maintains shares target, Buy rating post-NCI deal By Investing.com - Investing.com Canada
Likelihood of Approval and Phase Transition Success Rate ModelTuspetinib in Chronic Myelomonocytic Leukemia (CMML) - GlobalData
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials - The Manila Times
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML - GlobeNewswire
Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials - StockTitan
Aptose Biosciences Inc (APTO) Has A Gold Mine On Its Hands - Stocks Register
Aptose Biosciences CEO William Rice acquires $20,000 in shares By Investing.com - Investing.com Australia
Aptose Biosciences CEO William Rice acquires $20,000 in shares - Investing.com
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewswire
Aptose Biosciences Boosts Capital with $8M Offering - TipRanks
Aptose Biosciences Completes $8M Public Offering with Insider Participation | APTO Stock News - StockTitan
Form 424B4 Aptose Biosciences Inc. - StreetInsider.com
SEC Form 424B4 filed by Aptose Biosciences Inc. - Quantisnow
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose sets $8 million target in stock and warrant offering By Investing.com - Investing.com Australia
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views - Benzinga
Aptose sets $8 million target in stock and warrant offering - Investing.com India
Aptose Biosciences Inc Stock (APTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):